Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 4/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19001341 | 1.00 | LMNA (0.58) | LMNASMN1; SMN2NPC1HPGDCASP3 | |
| SCHEMBL18998163 | 0.88 | HPGD (0.56) | LMNASMN1; SMN2NPC1HPGDCASP3 | |
| SCHEMBL18997661 | 0.87 | LMNA (0.63) | LMNASMN1; SMN2NPC1HPGDCASP3 | |
| SCHEMBL18997757 | 0.85 | LMNA (0.60) | LMNASMN1; SMN2NPC1HPGDCASP3 | |
| SCHEMBL25314636 | 0.84 | LMNA (0.56) | LMNASMN1; SMN2NPC1HPGDCASP3 | |
| SCHEMBL23598886 | 0.83 | ESR1 (0.65) | LMNASMN1; SMN2NPC1HPGDCASP3 | |
| SCHEMBL31337018 | 0.83 | ESR1 (0.65) | LMNASMN1; SMN2NPC1HPGDCASP3 | |
| SCHEMBL23579984 | 0.82 | CCNC (0.66) | LMNASMN1; SMN2NPC1HPGDCASP3 | |
| SCHEMBL25314328 | 0.82 | LMNA (0.54) | LMNASMN1; SMN2NPC1HPGDCASP3 | |
| SCHEMBL31336922 | 0.82 | CCNC (0.66) | LMNASMN1; SMN2NPC1HPGDCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | claimed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | LMNA 1425/4885SMN1; SMN2 1602/4885NPC1 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.